Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARVN Arvinas	$7.32 +0.3%	$7.46	$5.90 ▼ $29.61	$537.42M	2.22	2.02 million shs	1.42 million shs
ETON Eton Pharmaceuticals	$17.30 +1.2%	$15.00	$4.23 ▼ $21.48	$463.95M	1.13	353,790 shs	214,068 shs
GNLX Genelux	$3.78 +9.9%	$3.26	$1.95 ▼ $5.89	$142.78M	-0.32	87,582 shs	142,823 shs
PRME Prime Medicine	$3.55 +10.2%	$3.50	$1.11 ▼ $5.17	$477.74M	2.39	2.53 million shs	3.10 million shs

The Best High-Yield Dividend Stocks for 2025

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARVN Arvinas	0.00%	+3.24%	-7.22%	+12.44%	-70.87%
ETON Eton Pharmaceuticals	0.00%	+1.53%	+12.56%	-12.67%	+317.87%
GNLX Genelux	0.00%	+6.18%	+8.93%	+46.51%	+84.39%
PRME Prime Medicine	0.00%	-0.56%	-18.39%	+175.19%	-19.32%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARVN Arvinas	4.0845 of 5 stars	4.3	3.0	3.7	2.5	1.3
ETON Eton Pharmaceuticals	2.2968 of 5 stars	3.5	1.0	2.8	1.7	0.6
GNLX Genelux	1.6647 of 5 stars	3.6	2.0	2.3	0.0	0.0
PRME Prime Medicine	2.7246 of 5 stars	3.4	1.0	1.3	5.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARVN Arvinas	2.55	Moderate Buy	$19.76	169.99% Upside
ETON Eton Pharmaceuticals	3.00	Buy	$29.67	71.48% Upside
GNLX Genelux	3.20	Buy	$17.75	369.58% Upside
PRME Prime Medicine	2.75	Moderate Buy	$8.92	151.17% Upside

Current Analyst Ratings Breakdown

Latest GNLX, PRME, ARVN, and ETON Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/8/2025	PRME Prime Medicine	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$12.00 ➝ $10.00
8/7/2025	ARVN Arvinas	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$24.00 ➝ $18.00
8/7/2025	ARVN Arvinas	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$19.00 ➝ $16.00
8/7/2025	ARVN Arvinas	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$16.00 ➝ $15.00
7/23/2025	GNLX Genelux	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
7/16/2025	PRME Prime Medicine	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$8.00
6/2/2025	ARVN Arvinas	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$24.00
6/2/2025	ARVN Arvinas	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Market Perform	$10.00 ➝ $9.00
6/1/2025	ARVN Arvinas	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/29/2025	ETON Eton Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$33.00 ➝ $35.00
5/27/2025	PRME Prime Medicine	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral	$10.00 ➝ $1.50

(Data available from 8/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARVN Arvinas	$263.40M	2.04	N/A	N/A	$8.30 per share	0.88
ETON Eton Pharmaceuticals	$39.01M	11.89	N/A	N/A	$0.89 per share	19.44
GNLX Genelux	$10K	14,277.06	N/A	N/A	$0.63 per share	6.00
PRME Prime Medicine	$4.96M	96.30	N/A	N/A	$1.37 per share	2.59

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARVN Arvinas	-$198.90M	-$1.01	N/A	N/A	N/A	-19.47%	-12.01%	-6.97%	10/29/2025 (Estimated)
ETON Eton Pharmaceuticals	-$3.82M	-$0.16	N/A	34.60	N/A	-7.10%	-0.73%	-0.22%	11/11/2025 (Estimated)
GNLX Genelux	-$29.87M	-$0.86	N/A	N/A	N/A	N/A	-107.47%	-83.14%	N/A
PRME Prime Medicine	-$198.13M	-$1.56	N/A	N/A	N/A	N/A	-107.87%	-74.97%	N/A

Latest GNLX, PRME, ARVN, and ETON Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/7/2025	Q2 2025	ETON Eton Pharmaceuticals	-$0.01	-$0.10	-$0.09	-$0.10	$16.71 million	$18.93 million
8/7/2025	Q2 2025	GNLX Genelux	-$0.22	-$0.20	+$0.02	-$0.20	N/A	N/A
8/6/2025	Q2 2025	ARVN Arvinas	-$0.87	-$0.84	+$0.03	-$0.84	$34.42 million	$22.40 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARVN Arvinas	N/A	N/A	N/A	N/A	N/A
ETON Eton Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
GNLX Genelux	N/A	N/A	N/A	N/A	N/A
PRME Prime Medicine	$1.45	40.73%	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARVN Arvinas	N/A	5.64	5.64
ETON Eton Pharmaceuticals	1.14	1.77	1.16
GNLX Genelux	N/A	4.18	4.18
PRME Prime Medicine	N/A	6.50	6.50

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARVN Arvinas	95.19%
ETON Eton Pharmaceuticals	27.86%
GNLX Genelux	37.33%
PRME Prime Medicine	70.37%

Insider Ownership

Company	Insider Ownership
ARVN Arvinas	4.73%
ETON Eton Pharmaceuticals	16.03%
GNLX Genelux	8.80%
PRME Prime Medicine	22.74%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARVN Arvinas	420	73.42 million	69.95 million	Optionable
ETON Eton Pharmaceuticals	20	26.82 million	22.52 million	Optionable
GNLX Genelux	10	37.77 million	34.45 million	Not Optionable
PRME Prime Medicine	234	134.57 million	100.38 million	Optionable

GNLX, PRME, ARVN, and ETON Headlines

Recent News About These Companies

Analysts Set Prime Medicine, Inc. (NYSE:PRME) Target Price at $8.92

August 21 at 2:18 AM | americanbankingnews.com

Positive Signs As Multiple Insiders Buy Prime Medicine Stock

August 20, 2025 | uk.finance.yahoo.com

Prime Medicine, Inc. (NYSE:PRME) Given Consensus Rating of "Moderate Buy" by Analysts

August 19, 2025 | marketbeat.com

Analysts Set Expectations for Prime Medicine FY2025 Earnings

August 16, 2025 | marketbeat.com

Q3 EPS Estimates for Prime Medicine Cut by HC Wainwright

August 16, 2025 | marketbeat.com

HC Wainwright Cuts Earnings Estimates for Prime Medicine

August 16, 2025 | americanbankingnews.com

Chardan Capital Lowers Prime Medicine (NYSE:PRME) Price Target to $10.00

August 10, 2025 | marketbeat.com

Prime Medicine, Inc.: Strong Buy Rating Backed by Promising Pipeline and Robust Financial Position

August 8, 2025 | tipranks.com

PRME Revenue Misses by 73%

August 8, 2025 | aol.comA

Prime Medicine, Inc. (PRME) Reports Q2 Loss, Lags Revenue Estimates

August 7, 2025 | zacks.com

Prime Medicine Reports Second Quarter 2025 Financial Results and Provides Business Updates

August 7, 2025 | globenewswire.com

Prime Medicine (NYSE:PRME) Trading Down 6.7% - Here's What Happened

August 6, 2025 | marketbeat.com

Prime Medicine Holds Special Stockholder Meeting

August 5, 2025 | tipranks.com

Prime Medicine (NYSE:PRME) Shares Gap Up on Insider Buying Activity

August 5, 2025 | marketbeat.com

Friday’s Insider Trades: Key Buys and Sells in US Stocks Revealed

August 4, 2025 | investing.com

Arch Venture Partners Xii, Llc Purchases 3,030,300 Shares of Prime Medicine, Inc. (NYSE:PRME) Stock

August 2, 2025 | marketbeat.com

Prime Medicine, Inc. (NYSE:PRME) Major Shareholder Arch Venture Partners Xii, Llc Purchases 3,030,300 Shares

August 2, 2025 | insidertrades.com

Prime Medicine Halts Sales Agreement Prospectus

August 1, 2025 | theglobeandmail.com

Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

August 1, 2025 | finance.yahoo.com

Prime Medicine Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

August 1, 2025 | globenewswire.com

Prime Medicine (NYSE:PRME) Shares Gap Down - Here's Why

August 1, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNLX, PRME, ARVN, and ETON Company Descriptions

Arvinas NASDAQ:ARVN

$7.32 +0.02 (+0.27%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$7.45 +0.13 (+1.78%)

As of 08/22/2025 06:32 PM Eastern

Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins. Its product pipeline includes Bavdegalutamide and ARV-766, investigational orally bioavailable PROTAC protein degraders for the treatment of men with metastatic castration-resistant prostate cancer, which are in Phase 1/2 clinical trials; and ARV-471, an orally bioavailable estrogen receptor degrading PROTAC targeted protein degrader for the treatment of patients with locally advanced or metastatic estrogen receptor+/human epidermal growth factor receptor 2-breast cancer, which is Phase 3 clinical trial. Arvinas, Inc. has collaborations with Pfizer Inc., Genentech, Inc., F. Hoffman-La Roche Ltd., Carrick Therapeutics Limited, and Bayer AG. The company was founded in 2013 and is based in New Haven, Connecticut.

Eton Pharmaceuticals NASDAQ:ETON

$17.30 +0.21 (+1.23%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$17.26 -0.05 (-0.26%)

As of 08/22/2025 04:10 PM Eastern

Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing, acquiring, and commercializing pharmaceutical products for rare diseases. The company offers ALKINDI SPRINKLE, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; Betaine Anhydrous for the treatment of homocystinuria; and Nitisinone for the treatment of tyrosinemia type 1. It also provides Zeneo hydrocortisone autoinjector for the treatment of adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.

Genelux NASDAQ:GNLX

$3.78 +0.34 (+9.88%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$3.78 +0.01 (+0.13%)

As of 08/22/2025 06:38 PM Eastern

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

Prime Medicine NYSE:PRME

$3.55 +0.33 (+10.25%)

Closing price 08/22/2025 04:00 PM Eastern

Extended Trading

$3.57 +0.02 (+0.56%)

As of 08/22/2025 07:40 PM Eastern

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address the spectrum of diseases by deploying gene editing technology. The company offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. It has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. The company was incorporated in 2019 and is based in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time